Solagran

Solagran is an Australian-based biotechnology company focused on the research, development, and commercialization of "Bioeffectives," which are complex mixtures of biologically active compounds derived from coniferous tree needles. The company's primary pharmaceutical product, Ropren, is a polyprenol-based substance approved in Russia for the treatment of various liver disorders, including chronic hepatitis and cirrhosis. Solagran's research also extends into neurology, where it has investigated the potential of Bioeffectives to treat neurodegenerative conditions like Alzheimer's disease by supporting the dolichol cycle and mitochondrial health. Although the company achieved significant regulatory milestones in Russia, it faced financial and administrative challenges that led to its delisting from the Australian Securities Exchange (ASX) in 2012. Today, the legacy of its technology continues through various international partnerships and specialized natural health products.